Singapore markets closed

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.91+1.07 (+12.12%)
As of 10:04AM EDT. Market open.
Currency in USD

Valuation measures

Market cap (intra-day) 52.06B
Enterprise value 31.46B
Trailing P/E N/A
Forward P/E 119.06
PEG Ratio (5 yr expected) 1-0.19
Price/sales (ttm)278.59
Price/book (mrq)4.02
Enterprise value/revenue 3197.39
Enterprise value/EBITDA 7-12.14

Trading information

Stock price history

Beta (5Y monthly) 0.76
52-week change 312.04%
S&P500 52-week change 347.33%
52-week high 333.79
52-week low 37.36
50-day moving average 39.69
200-day moving average 310.90

Share statistics

Avg vol (3-month) 314.52M
Avg vol (10-day) 36.09M
Shares outstanding 5208.31M
Implied shares outstanding 6N/A
Float 204.2M
% held by insiders 11.71%
% held by institutions 132.21%
Shares short (30 Mar 2021) 454.64M
Short ratio (30 Mar 2021) 45.93
Short % of float (30 Mar 2021) 426.67%
Short % of shares outstanding (30 Mar 2021) 426.23%
Shares short (prior month 25 Feb 2021) 450.23M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:4
Last split date 305 Jun 2014

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Dec 2020


Profit margin 0.00%
Operating margin (ttm)-1,674.25%

Management effectiveness

Return on assets (ttm)-22.68%
Return on equity (ttm)-71.79%

Income statement

Revenue (ttm)7.41M
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)1,896.70%
Gross profit (ttm)-86.83M
EBITDA -120.5M
Net income avi to common (ttm)-166.41M
Diluted EPS (ttm)-1.07
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)411.64M
Total cash per share (mrq)1.98
Total debt (mrq)39.05M
Total debt/equity (mrq)8.47
Current ratio (mrq)11.30
Book value per share (mrq)2.47

Cash flow statement

Operating cash flow (ttm)-177.98M
Levered free cash flow (ttm)-109.58M